Please use this identifier to cite or link to this item:
|Title:||Clozapine combination and augmentation strategies in patients with schizophrenia - recommendations from an international expert survey among the treatment response and resistance in psychosis (TRRIP) working group||Authors:||Wagner, Elias
Kane, John M.
Correll, Christoph U.
Honer, William G.
Lee, Jimmy Chee Keong
|Issue Date:||2020||Source:||Wagner, E., Kane, J. M., Correll, C. U., Howes, O., Siskind, D., Honer, W. G., Lee, J. C. K., Falkai, P., Schneider-Axmann, T. & Hasan, A. (2020). Clozapine combination and augmentation strategies in patients with schizophrenia - recommendations from an international expert survey among the treatment response and resistance in psychosis (TRRIP) working group. Schizophrenia Bulletin, 46(6), 1459-1470. https://dx.doi.org/10.1093/schbul/sbaa060||Journal:||Schizophrenia Bulletin||Abstract:||Evidence for the management of inadequate clinical response to clozapine in treatment-resistant schizophrenia is sparse. Accordingly, an international initiative was undertaken with the aim of developing consensus recommendations for treatment strategies for clozapine-refractory patients with schizophrenia.||URI:||https://hdl.handle.net/10356/150073||ISSN:||0586-7614||DOI:||10.1093/schbul/sbaa060||Rights:||© 2020 The Author(s). Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved.||Fulltext Permission:||none||Fulltext Availability:||No Fulltext|
|Appears in Collections:||LKCMedicine Journal Articles|
Updated on May 17, 2022
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.